Cassava Sciences (SAVA) News Today $2.11 -0.01 (-0.47%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.09 -0.02 (-0.95%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cassava Sciences Inc.May 16, 2025 | barrons.comCassava Technologies, Zindi collaborate on AI servicesMay 12, 2025 | msn.comNew report finds concerning levels of lead in popular cassava itemsMay 12, 2025 | yahoo.comCassava Reports Q1 2025 Financials Results, Provides Business UpdateMay 9, 2025 | finance.yahoo.comInvesco Ltd. Trims Stock Position in Cassava Sciences, Inc. (NASDAQ:SAVA)Invesco Ltd. lessened its stake in Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) by 95.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,408 shares of the company's stock after sellingMay 8, 2025 | marketbeat.comZindi Teams Up with Cassava to Spotlight African AI TalentMay 6, 2025 | msn.comZindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovationMay 5, 2025 | msn.comCassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSCMay 1, 2025 | globenewswire.comCassava Sciences appoints new SVP of Clinical DevelopmentApril 23, 2025 | investing.comCassava Sciences chief medical officer James Kupiec to retireApril 22, 2025 | markets.businessinsider.comCassava's Chief Medical Officer to retireApril 21, 2025 | msn.comCassava Sciences Chief Medical Officer Kupiec RetiresApril 21, 2025 | marketwatch.comCassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical DevelopmentApril 21, 2025 | globenewswire.comShort Interest in Cassava Sciences, Inc. (NASDAQ:SAVA) Declines By 17.8%Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 11,880,000 shares, a decrease of 17.8% from the February 28th total of 14,450,000 shares. Based on an average trading volume of 2,270,000 shares, the short-interest ratio is presently 5.2 days. Currently, 27.1% of the shares of the stock are sold short.April 3, 2025 | marketbeat.comNotable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focusMarch 30, 2025 | msn.comCassava Sciences must face malicious prosecution lawsuit over Alzheimer's drugMarch 26, 2025 | reuters.comHC Wainwright Reiterates Neutral Rating for Cassava Sciences (NASDAQ:SAVA)HC Wainwright reaffirmed a "neutral" rating and issued a $2.00 price objective on shares of Cassava Sciences in a research note on Tuesday.March 26, 2025 | marketbeat.comCassava ends simufilam Alzheimer’s programme after second Phase III failureMarch 26, 2025 | finance.yahoo.comCassava Sciences announces Phase 3 REFOCUS-ALZ did not meet primary endpointMarch 26, 2025 | markets.businessinsider.comCassava Sciences to discontinue all efforts to develop simufilam in Alzheimer’sMarch 26, 2025 | markets.businessinsider.comCassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains HopefulMarch 26, 2025 | msn.comCassava to phase out Alzheimer’s program by Q2March 25, 2025 | msn.comCassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be DiscontinuedMarch 25, 2025 | marketwatch.comCassava to discontinue development of Alzheimer's disease drugMarch 25, 2025 | msn.comCassava Sciences' controversial Alzheimer's drug fails in second late-stage studyMarch 25, 2025 | msn.comCassava Sciences Reports Topline Phase 3 REFOCUS-ALZ DataMarch 25, 2025 | globenewswire.comCassava Sciences: Downside From Alzheimer's Results Still Possible Despite New DevelopmentsMarch 21, 2025 | seekingalpha.comCassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comHC Wainwright Lifts Earnings Estimates for Cassava SciencesCassava Sciences, Inc. (NASDAQ:SAVA - Free Report) - Equities research analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for shares of Cassava Sciences in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst V. Bernardino now anticipates that theMarch 8, 2025 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Given Neutral Rating at HC WainwrightHC Wainwright restated a "neutral" rating on shares of Cassava Sciences in a research note on Tuesday.March 5, 2025 | marketbeat.comCassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term ValueMarch 4, 2025 | seekingalpha.comH.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might revealMarch 4, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)March 4, 2025 | markets.businessinsider.comCassava Sciences, Inc.: Cassava Sciences Reports 2024 Financial Results and Provides Business UpdateMarch 4, 2025 | finanznachrichten.deCassava Sciences reports Q4 EPS (57c) vs (50c) last yearMarch 3, 2025 | markets.businessinsider.comCassava Sciences (NASDAQ:SAVA) Posts Quarterly Earnings Results, Beats Estimates By $0.42 EPSCassava Sciences (NASDAQ:SAVA - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.42.March 3, 2025 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Announces Quarterly Earnings ResultsCassava Sciences (NASDAQ:SAVA - Get Free Report) issued its earnings results on Monday. The company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.99) by $0.42.March 3, 2025 | marketbeat.comCassava Sciences Reports 2024 Financial Results and Provides Business UpdateMarch 3, 2025 | globenewswire.comH.C. Wainwright Reaffirms Their Hold Rating on Cassava Sciences (SAVA)February 28, 2025 | markets.businessinsider.comCassava Sciences stock jumps on new patent licenseFebruary 27, 2025 | za.investing.comCassava Sciences Licenses Simufilam Method of Treatment PatentFebruary 27, 2025 | markets.businessinsider.comBook review: 'Doctored' investigates twists and turns of Alzheimer's drug scandalFebruary 22, 2025 | yahoo.comCassava Sciences (SAVA) to Release Earnings on WednesdayCassava Sciences (NASDAQ:SAVA) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comSAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud LawsuitFebruary 10, 2025 | prnewswire.comCassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVAFebruary 10, 2025 | globenewswire.comCassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law ...February 10, 2025 | gurufocus.comCassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVAFebruary 10, 2025 | prnewswire.comHow greed and profit fueled one failed Alzheimer drugFebruary 10, 2025 | nypost.comSAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVAFebruary 9, 2025 | globenewswire.comFINAL SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Join the Class Action LawsuitFebruary 9, 2025 | investing.com Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address SAVA Media Mentions By Week SAVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAVA News Sentiment▼0.000.75▲Average Medical News Sentiment SAVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAVA Articles This Week▼08▲SAVA Articles Average Week Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Precigen News Today Prothena News Today Kamada News Today Verve Therapeutics News Today Autolus Therapeutics News Today Oruka Therapeutics News Today Revance Therapeutics News Today ABIVAX Société Anonyme News Today Sana Biotechnology News Today Rapport Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAVA) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAVA Stock Free SAVA Stock Alerts